Novartis CMO John Tsai
October 26, 2020 07:23 AM EDT
R&D

No­var­tis suc­ceeds where Alex­ion failed, com­ing up with a win for a prized as­set in a rare kid­ney dis­or­der

Jason Mast

Editor

Three months af­ter Alex­ion stum­bled, No­var­tis de­clared an­oth­er Phase II suc­cess for a drug it hopes can carve out sig­nif­i­cant new in­di­ca­tions and po­ten­tial­ly …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times